Form 483

Noven Pharmaceuticals, Inc. Form 483, 2009-02-06

FDA issued a Form 483 to Noven Pharmaceuticals, Inc. on 2009-02-06 with 9 public-safe observations.

483· Form 483 issued9 observations

Noven Pharmaceuticals, Inc. · Miami, United States · Issued February 6, 2009

Overview

  • 9 public-safe observations are available for this inspection.
  • 9 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

6 Feb 2009
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Ileana Barreto-Pettit, Sarah E Mcmullen

6 Feb 2009
21 CFR 211.84(d)(2)

Reports of Analysis (Components)

Cited by Ileana Barreto-Pettit, Sarah E Mcmullen

6 Feb 2009
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Ileana Barreto-Pettit, Sarah E Mcmullen

6 Feb 2009
21 CFR 211.110(a)

Control procedures to monitor and validate performance

Cited by Ileana Barreto-Pettit, Sarah E Mcmullen

6 Feb 2009
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Ileana Barreto-Pettit, Sarah E Mcmullen

Inspected site

NPNoven Pharmaceuticals, Inc.Miami, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.100(a)Cited across public-safe Form 483 observations1x
21 CFR 211.110(a)Cited across public-safe Form 483 observations1x
21 CFR 211.160(b)Cited across public-safe Form 483 observations1x
21 CFR 211.160(b)(1)Cited across public-safe Form 483 observations1x
21 CFR 211.165(d)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.198(a)Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(2)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 9 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere